July 28, 2026
Claris Biotherapeutics
Claris Biotherapeutics secures $118M Series B funding to advance CSB-001, a pharmacologic therapy for limbal stem cell deficiency.
- Round
- Series B
- Amount raised
- $118M
- Lead investor
- —
- Industry
- —
- Headquarters
- United States
- Employees
- —
- Website
- —
- —
Source: AllSci